Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Tue, 19.12.2023
LION E-Mobility AG
Preparing for growth following 2023 as transition year
Topcic: LION published its solid 9M figures, which should be followed by a
2024 marked by strong growth and op. improvements. The recent share price
weakness provides a good risk/reward opportunity, in our view.
Solid 9M performance amid significant operational changes. Throughout H1
'23, [ … ]
Mon, 18.12.2023
Energiekontor AG
First Berlin Equity Research hat ein Research Update zu Energiekontor AG
(ISIN: DE0005313506) veröffentlicht. Analyst Dr. Karsten von Blumenthal
bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 116,00 auf
EUR 134,00.
Zusammenfassung:
Energiekontor (EKT) hat ein großes schottisches Windparkprojekt verkauft
und [ … ]
Mon, 18.12.2023
Rubean AG
PhonePOS rollout is starting right now; chg
Topic: After Rubean 1) solved its liquidity issues, 2) finally published
its FY22 figures that were in line with expectations and 3) announced
several promising partnerships, we are more optimistic that the rollout of
POS is starting right now and should have the potential to ramp-up sales.
Liquidit [ … ]
Mon, 18.12.2023
Nynomic AG
Bolt-on acquisition with high synergy potential; chg.
Topic: Nynomic announced the 100% acquisition of art photonic (13th pillar
of the Nynomic group), which should be highly value accretive during the
coming years thanks to significant synergy potential.
In detail, art photonic is a Berlin-based expert in the development and
production of hi [ … ]
Fri, 15.12.2023
HAEMATO AG
Delisting of the HAEMATO share to take place from February 2023; price
potential not yet exhausted; GBC-rating and GBC-price target suspended
HAEMATO has announced the termination of the inclusion of the shares in the
open market of 30 November 2023. The shares are to be delisted after expiry
of the notice period, at the latest by the end [ … ]
Fri, 15.12.2023
MLP SE
Prepared for the future - Analyst meeting feedback
Topic: MLP recently hosted its annual analyst meeting and gave insights
into strategic developments:
Advanced digitalization: On group level as well as for all MLP consultants,
the company has invested heavily into its digitalization. For example, AI
enabled robotic process automations signif [ … ]
Thu, 14.12.2023
Rover Metals Corp.
Cabin Lake offered for sale – Focus on Lithium assets
With a strict focus on the Let’s Go Lithium project in Nevada and the IML
project in the Northwest Territories, Rover Metals has announced that it
intends to offer its 100% owned Cabin Lake gold project for sale. Located
110 km northwest of Yellowknife at the northern end of [ … ]
Thu, 14.12.2023
Flughafen Wien AG
Solid November traffic figures underpin sound operations
Topic: Yesterday, FWAG released Nov '23 traffic results in line with
seasonality and our estimates.
In November, 2.67m passengers (+14% yoy; 92% of 2019 levels) were handled
by FWAG, in line with seasonality and our estimates (eNuW: 2.63m). While
the 8pp gap to 2019 levels can be explai [ … ]
Wed, 13.12.2023
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin hat seine bisherige
Buy-Empfehlung und sein bisheriges Kursziel von EUR 34,00 wegen des
bevorstehenden Delistings zurückgenommen.
Zusammenfassung:
Haemato wird die Notierung ihrer Aktien im Open Market der Frank [ … ]
Wed, 13.12.2023
MPH Health Care AG
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG
(ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 62,00.
Zusammenfassung:
Der NAVPS lag zum Neunmonatszeitpunkt bei €50,40 gegenüber €31,90 in 9M/22
(+58%) Die schlep [ … ]